Scottish Medicines Consortium

Resubmission

Biphasic Insulin Aspart (NovoMix30°) (No. 06/02)
Novo Nordisk Ltd
Summary of Recommendation

9 May 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**ADVICE**

Recommended for general use within NHS Scotland.

**RECOMMENDATION**

In trials of 12 weeks duration, biphasic insulin aspart has demonstrated similar effects on HbA1c levels to biphasic human insulin 30 and biphasic insulin lispro Mix 25.

Biphasic insulin aspart 30 has demonstrated similar effects to its competitor insulins and therefore is an effective treatment for diabetes at broadly similar costs.

Professor David H Lawson
Chairman